Market intelligence
News & enforcement.
The regulatory actions, lawsuits, and industry shifts moving the research-peptide market. Every item links to its source and is tagged by how much weight it deserves — a primary FDA or court document is not the same as a forum rumor, and we mark which is which.
1 record of 17
Source
Topic
FDA Warning Letter to SwissChems (MARCS-CMS 695663)
FDA cited SwissChems for marketing semaglutide and retatrutide as unapproved new drugs intended for human use, using the company's own product-page language as evidence. Issued the same day as letters to Summit Research Peptides, Prime Peptides and Xcel Peptides in a coordinated peptide/GLP-1 warning-letter wave.
Primary government, court, or regulatory document